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FIELD EVALUATION OF AN ORF VACCINE IN SHEEP AND
GOAT FLOCKS WITH HIGH NEONATAL MORTALITY*
PROCENA ORF VAKCINE NA TERENU KOD STADA OVACA I KOZA
SA VISOKOM NEONATALNOM SMRTNO[]U
N. D. Giadinis, G. Filliusis, S. Q. Lafi, N. Panousis, K. Pourliotis,
J. Bojkovski, H. Karatzias**
A high percent of annual neonatal mortality attributed to orf infec-
tion was observed between 2001 and 2004 in 2 sheep and 2 mixed
(sheep and goat) flocks of Northern Greece. In order to protect the neo-
natal lambs and kids from orf infection a commercially available live orf
vaccine was used. Pregnant sheep and goats were vaccinated subcu-
taneously a month before parturition, while 10 sheep and 10 goats in
each flock remained unvaccinated and were used as negative con-
trols. The vaccine was significantly effective (P<0.05) in reducing the
orf lesions and the mortality rate in lambs and kids of the 4 flocks. Dur-
ing the next year 3 of the 4 flocks were revaccinated. A significantly low
percentage of orf lesions and neonatal mortality continued to occur in
revaccinated flocks, while a significant percentage (P<0.05) of orf le-
sions and neonatal mortality reappeared in the nonrevaccinated flock.
The antibody titres in vaccinated sheep and goats were increased sig-
nificantly on days 60 and 105 post-vaccination, while the titres in the
controls remained low (P<0.05).
Key words: lambs, kids, mortality, protection, orf, live vaccine
Contagious ecthyma (synonyms: contagious pustular dermatitis, orf,
contagious pustular stomatitis, malignant aphtha, sore mouth, scabby mouth) is
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an infectious viral disease affecting mainly sheep and goats, but also reindeer and
musk oxen. Experimental infection has been achieved in cattle, rabbits, horses
and monkeys (Michelsen PGE, 2002). The orf virus is a zoonotic pathogen, as hu-
mans are also susceptible to orf, which is an occupational hazard of those that
handle sheep and goats (Robinson AJ, Balassu TC, 1981). It has worldwide preva-
lence and causes noticeable economic effect through loss of condition, mastitis,
abandonment and related deaths (Scott DW et al., 1984; Scott DW, 1988), al-
though in some cases the disease can have no economic impact (McElroy MC
and Bassett HF, 2007).
The orf causative agent is a DNA epitheliotropic Parapoxvirus (family
Poxviridae) virus. Genetic heterogeneity of the orf virus isolates circulate in differ-
ent geographic regions as concluded from several molecular studies (Mazur C et
al., 2000; Kottaridi C et al., 2006). The orf virus infects damaged or scarified skin
and replicates in regenerating epidermal keratinocytes (McKeever DJ et al., 1988;
Haig DM and McInnes CJ, 2002; Haig DM et al., 2002). The clinical progression of
the infection is erythema, papule, vesicle, pustule and scab. The virus is shed with
the scab to seed the environmental pool, where it survives for a long time (Reid
HW, 2002). Transmission occurs through direct and indirect (fomite) contact
(Scott DW et al., 1984).
In sheep and goats, the disease usually occurs in young animals 3-6
months old, although neonatal lambs and kids aged 10-12 days old can be se-
verely affected as well. In naive flocks the disease can affect also adult animals
(Radostits OM et al., 2000; Navarre CB et al., 2002). Clinical signs include
papules, vesicles, pustules and scabs. The lesions usually heal in 2-4 weeks
(Scott DW et al., 1984; Smith MC and Sherman DM, 1994; Reid HW, 2002). In
lambs they are distributed around the mouth and nostrils, along the gums and in
the oral cavity, on the thigh, axilla, poll, genitalia, lower limbs, coronet and ewe ud-
der (Reid HW, 2002). In kids the lesions are distributed on the lips, muzzle, eyelids,
oral cavity, udder, teats and feet (Scott DW., 1988). Affected animals usually ex-
hibit a decrease in feed consumption and some become depressed, anorectic
and febrile (Scott DW et al., 1984; Scott DW, 1988). Complications of contagious
ecthyma include secondary bacterial infections (respiratory, gastrointestinal, in-
tegumentary), myiasis, mastitis and lameness (Scott DW et al., 1984; Scott DW.,
1988; Anderson DE et al., 2002). The morbidity can reach up to 100 % and the
case fatality rate usually ranges between 5-15 %, although case fatality rates, up to
75 % (Radostits OM et al., 2000) and mortality up to 78 % (Darbyshire JH, 1961)
have been reported.
The host immune response controlling orf virus replication in the skin
of infected animals is based on CD4 (+) T-cells and orf-virus-specific antibodies
(McKeever DJ and Reid HD, 1987; McKeever DJ et al., 1987; Lloyd JB et al., 2000).
Since the orf virus can produce a series of immune-modulator and virulence pro-
teins, the host immune response is not effective to eliminate the virus rapidly (Haig
DM, 2006). In primary infections, the virus is able to replicate for a period of time
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before the host can mount an effective immune response. On the contrary, in re-
infections, the immune memory response ensures a rapid accumulation of host
immune effector molecules and the virus is contained and eliminated more rapidly
than in primarily infections (Haig DM and McInnes CJ, 2002). Nevertheless, rein-
fections are frequent.
Mild infections are usually self-limiting (Clarckson MJ, Faull WB,1990;
Michelsen PGE, 2002). In more severe infections various treatments have been
applied, but results generally were not satisfactory (Reeid HW, 2002). Therefore, a
great interest exists for disease prevention. Only live vaccines are recommended.
The traditional vaccine virus is prepared from the infected scabs of orf virus le-
sions in sheep and is used to vaccinate animals by scratching with an applicator.
Up to date, several studies were conducted to evaluate the efficacy of live vac-
cines against orf in sheep. However, there is a lack of accord between the re-
searchers about their efficacy (Valder WA et al., 1979; Mayr A et al., 1981; Buddle
BM and Pulford HD, 1984; Buddle, BM et al., 1984; Pye D, 1990; Nettleton PF et al.,
1996). From these studies, only some (Mayr A et al., 1981) have conducted a field
trial, while all the other trials have been conducted in controlled conditions. The
majority of these efficacy trials have been accomplished in sheep, while data for
goat vaccination is very limited in literature.
Considering all the above information, the aim of this study was to as-
sess the protection ability of a commercially available live vaccine, under field
conditions in 4 small ruminant flocks in Greece, that had high lamb and kid mortal-
ity attributed to severe orf infections.
Animals / @ivotinje
The main experimental study was conducted in 4 flocks of northern
Greece (Macedonia and Thrace) in the year 2005. The next year, 2006, the same 4
flocks were monitored for their health status and the vaccine clinical efficacy.
Flock 1. consisted of Lacaune sheep and was reared in Kozani area of
West Macedonia. Flock 2. consisted of Lacaune and Friesian sheep and was
reared in Xanthi area (Thrace). Flock 3. was mixed and consisted of Chios sheep
(purebred and crosses with other local dairy breeds) and goats of local dairy
breeds; the flock was reared in the Kavala area (East Macedonia). Flock 4. was
also mixed and consisted of purebred Chios sheep and goats of local dairy
breeds; this flock was reared in the Thessaloniki area (Central Macedonia).
During the past years (2001-2004) high neonatal mortality, attributed
to contagious ecthyma has been recorded in all flocks, as was confirmed by clini-
cal examination, histopathology and PCR.
The animals of the 4 flocks were reared under a closed intensive feed-
ing system. The adults were fed alfalfa hay, straw and a commercial concentrated
feed according to their dietary requirements (NRC, 1981; 1985). The neonatal
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Materials and methods / Materijal i metode rada
lambs and kids were suckling their mothers and had free access to alfalfa hay and
commercial concentrated feed. All the animals were free of ectoparasites, regu-
larly dewormed and vaccinated against clostridial infections.
Vaccine / Vakcina
The vaccine Ecthybel®, a product of Merial-France was used for this
study. It contains live ecthyma virus cultured in cells at least 2.5 x 104 PFU.
Experimental design / Plan eksperimenta
In order to achieve homogenous crops of lambs and kids all ewes and
does were estrus synchronized in June 2004. Each adult animal was also ear-
tagged and at 2.5 months of pregnancy was examined by ultrasonography for
their pregnancy status. In each flock, a month before the expected date of parturi-
tion (Day 0), all pregnant sheep and goats of each flock were separated from the
non-pregnant animals.
From each participated flock, 10 sheep and 10 goats were randomly
selected (a total of 40 sheep and 20 goats) as unvaccinated controls. From these
animals blood samples were taken by jugular vein puncture and then they re-
ceived a 1 ml subcutaneous injection of 0.9 % saline solution (Group 1 – control).
The remaining pregnant sheep (1060 totally) and goats (130 totally) in each flock
were vaccinated subcutaneously against orf virus (Group 2) with 1 ml of a com-
mercial live vaccine (Ecthybel®) according to the vaccine instructions. Before vac-
cination blood samples were taken from 10 sheep and 10 goats randomly se-
lected in each flock (40 sheep and 20 goats totally). After grouping, the animals of
the 2 groups remained separate and were monitored daily for their health status.
After parturition, their neonatal lambs and kids were also monitored daily. Lambs
or kids with orf lesions were treated and the dead ones were immediately necrop-
sied to identify the cause of death. Blood samples were also taken on days 60 and
105 post-vaccination from the adult animals.
The next lambing season (2006) the flocks 2, 3 and 4 were revacci-
nated as previously, while the owner of flock 1 refused to vaccinate his animals.
The neonatal lambs and kids of the 2 groups were attended for their health status
for 2 months.
Antibody determination / Odre|ivanje koncentracije antitela
The blood samples were centrifuged at 3000 rpm for 20 min and the
serum was kept at 4 oC. A commercial ELISA kit (Teqlab Rothe- Swizerland) based
on a specific antigen was used and the serum was tested in four subsequent ten-
fold dilutions. The samples were examined in duplicate for flock 2. One sample se-
ries was examined in the Laboratory of Microbiology and Infectious Diseases of
the Veterinary School of Thessaloniki-Greece and the other in the Veterinary
School of Hannover-Germany. For the other 3 flocks the samples were examined
only in Thessaloniki.
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Statistical analysis / Statisti~ke analize
Data were stored in a database and analyzed using SPSS 10.0 soft-
ware (SPSS, 2000). The statistically significant association was determined by the
Chi-squared test and the level of significance was P<0.05. In cases where the Chi-
squared test was not applicable (expected frequency less than 1 and over 20% of
expected frequencies less than 5), Fisher’s exact test was applied.
The vaccine efficacy assessment was based on the number of new-
born lambs and kids of the 2 groups (vaccinated and controls) with orf lesions, on
the neonatal mortality rate and on blood serum antibody levels of vaccinated and
unvaccinated ewes and does.
The vaccine was significantly effective (P<0.05) in reducing the orf le-
sions and the mortality in lambs and kids of the 4 flocks in total.
Flock 1. Fifteen out of 15 lambs (100 %) from unvaccinated mothers
(Group 1) had orf lesions at the age of 10-20 days and they all died despite treat-
ment. In dead lambs severe stomatitis and bronchopneumonia was observed at
necropsy. On the contrary, all the lambs (210 out of 210-100 %) of group 2 re-
mained healthy and no losses due to orf were recorded. Flock 2. Ten out of 20
lambs (50 %) from unvaccinated mothers (Group 1) had orf lesions when they
were 10-12 days old and they died despite treatment. At necropsy the same le-
sions as in lambs of flock 1 were observed. Five out of the 10 (25 %) other lambs of
Group 1 showed orf lesions and after treatment they survived, while the other 5
lambs (25 %) had no orf lesions and grow normally. Regarding Group 2 animals,
only 6 out of 230 lambs (2.6 %) had mild orf lesions at the commissures of the lips
and no deaths were recorded. Flock 3. All the lambs (18 out of 18-100 %) and kids
(15 out of 15-100 %) from unvaccinated mothers (Group 1) had orf lesions at the
age of 10-15 days and they died despite treatment. At necropsy severe stomatitis
and bronchopneumonia were also observed. Mild orf lesions at the lips were ob-
served in only 3 out of 700 (0.43 %) lambs of Group 2 and they were treated suc-
cessfully, while neither orf lesions nor deaths were found in kids (65 out of 65-
100 %) from vaccinated does. Flock 4. All the lambs (19 out of 19-100 %) and kids
(19 out of 19-100 %) from unvaccinated mothers (Group 1) had orf lesions when
they were 15 days old and all were treated. After treatment only 1 out of 19 lambs
survived (5.26 %), while all the kids died despite treatment. At necropsy they were
found to have severe stomatitis and bronchopneumonia. All the lambs (290 out of
290-100 %) and kids (160 out of 160-100 %) of Group 2 were fully protected. No orf
lesions and mortality attributed to the orf virus were recorded.
The 2nd year (2006), the flocks 2, 3 and 4 that were revaccinated 1
month before parturition had minimal losses due to orf infection. The 1st flock that
was not revaccinated had orf lesions in 80 % of the neonatal lambs and mortality in
51.74 % of neonatal lambs (150 out of 290). The deaths were attributed to severe
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Results / Rezultati
stomatitis and bronchopneumonia. The morbidity and mortality rate in unvacci-
nated flock 1 were significantly higher compared with the previous year (P<0.05).
No difference in antibody titres was recorded in the serological exami-
nation between the 2 laboratories. On Day 0 there were no significant differences
in mean antibody titres (P>0.05) of the animals in the 2 groups. Besides, there
were no significant differences in mean antibody titres of unvaccinated sheep and
goats (Group 1) on days 0, 60 and 105 (P>0.05). A statistically significant in-
crease (P<0.05) in mean antibody titres of sheep and goats among the 3 sam-
plings (105 day>60 day>0 day) of the vaccinated Group 2 was recorded. The an-
tibody titres in animals of Group 2 were significantly higher (P<0.05) than in
Group 1 on days 60 and 105.
The number of the animals of each flock and the losses of the previous
year (2004), before the experiment, are shown in Table 1. The mortality rates for
vaccinated and non-vaccinated flocks are shown in Table 2. Figure 1 shows the re-
sults of serological examination from sheep of flock 2.
Table 1. Number of animals and losses in the 4 flocks for the year 2004 /
Tabela 1. Broj `ivotinja i gubici kod 4 stada tokom 2004.
Flock No /
Stado broj
Adult animals /
Odrasle `ivotinje
Neonates /
Neonatalne `ivotinje
Dead /
Uginule
Alive /
@ive
Ewes /
Ovce
Does /
Koze
Lambs /
Jagnjad
Kids /
Jarad
Lambs /
Jagnjad
Kids /
Jarad
Lambs /
Jagnjad
Kids /
Jarad
1 200 - 300 - 297 - 3 -
2 200 - 290 - 275 - 15 -
3 500 50 750 95 220 30 530 65
4 200 100 290 200 150 50 140 150
Table 2. Lamb and kid mortality rate for vaccinated and non-vaccinated (control) sheep
and goat flocks /
Tabela 2. Stopa smrtnosti jagnjadi i jaradi kod vakcinisanih i nevakcinisanih (kontrolnih) stada ovaca i koza
Flock No /
Stado broj
Vaccinated sheep /
Vakcinisane ovce
Control sheep /
Kontrolne ovce
Vaccinated goats /
Vakcinisane koze
Control goats /
Kontrolne koze
1 0 % 100 % – –
2 0 % 50 % – –
3 0 % 100 % 0 % 100 %
4 0 % 94.74 % 0 % 100 %
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Although a number of proprietary treatments as well as homeopathic
preparations are available, the treatment of orf infections is usually not effective
(Reid HW, 2002). Moreover, the possible beneficial effects of treatment must be
weighed against the danger of zoonotic infection (Valder WA et al., 1979; Smith
MC and Sherman DM, 1994). Therefore, prevention measures of applying effec-
tive vaccination programs was essential, especially in flocks which experienced a
high neonatal mortality rate in the previous years despite the application of differ-
ent treatment protocols.
The use of orf vaccines in the field had a long story with controversial
aspects about their efficacy and safety. Although they can limit the severity of the
disease, they are not completely effective and vaccine strains may be the source
of outbreaks (Girlay JA et al., 1998). Nevertheless, their use is considered neces-
sary especially in cases with a high neonatal mortality rate, as has been shown in
the 4 flocks referred to in this study. Since there are no commercial vaccines
against orf virus licenced in the Greek market, a special licence was obtained from
the Ministry of Agriculture for the use of Ecthybel® that is available in France. In li-
terature, no available scientific information was found regarding the efficacy of this
commercial vaccine in the field, something that probably makes this trial more in-
teresting.
According to the vaccine instructions, pregnant animals should be
vaccinated one month before parturition. Otherwise, neonatal lambs or kids
should be vaccinated after the onset of the symptoms of the disease. In the pres-
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Discussion / Diskusija
Figure 1. Antibody titres in sheep of the 2 groups on days 0, 60 and 105 /
Slika 1. Titri antitela kod ovaca grupe 2 na dane 0, 60 i 105
Group 2 / Grupa 2
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ent study, it was decided to vaccinate only adult animals, because results of a pre-
vious preliminary study conducted in Greece (Giadinis N, 2006) indicated that
vaccination of neonatal lambs and kids with Ecthybel® was not effective.
Several trials for the evaluation of different orf vaccines had contra-
dictory results. Different routes of vaccine administration and only sheep of differ-
ent age and productive stage were used. Information regarding orf vaccination in
goats is limited. In fact, only one trial so far has been reported in Norway. Unfortu-
nately, the results of this trial were not reliable, as there was a contamination of the
vaccine with the Border disease virus (Loken T et al., 1991). The results from our
study could be the first field trial with orf vaccine in goats.
In the present study, pregnant sheep and goats were vaccinated 1
month before parturition. The vaccine was administered with subcutaneous injec-
tion, which is an easy way of administration and is the common route of admini-
stration for the majority of small ruminant vaccines (Mobini S et al., 2002). The
subcutaneous route to vaccinate sheep against orf has been used only by some
authors (Mayr et al., 1981), while skin scarification of the inner thigh or the axilla is
the most preferable route of orf vaccine administration (Buddle BM and Pulford
HD, 1984; Buddle BM, 1984; Scott DW, 1988; Clarckson MJ and Faull WB, 1990;
Pye D, 1990; Nettleton PF et al., 1996). Regarding the age and productive stage of
vaccinated animals, many researchers in order to achieve better efficacy pre-
ferred to vaccinate lambs and not adult animals (Buddle BM and Pulford HD,
1984; Buddle BM, 1984; Nettleton PF et al., 1996). Vaccination with the Scabivax®
(Coopers Pitman-Moore) was more effective when administered in lambs or in the
early or mid-gestation period of ewes (Clarckson MJ and Faull WB, 1990). In our
study, the vaccine administration 1 month before parturition to ewes and does
was effective without side effects. Our results are in accordance with the findings
of Mayr A et al. (1981), who vaccinated 4 sheep flocks with high lamb morbidity
and mortality due to orf infection. They found, that sheep vaccination in late preg-
nancy reduced significantly morbidity and minimized almost totally the neonatal
mortality. Lamb vaccination in the later study was also effective, but not as effec-
tive as in the vaccination of pregnant sheep.
The efficacy of vaccination in other trials differed. In Germany, Mayr A
et al. (1981) had similar problems in sheep flocks with high morbidity and mortality
and the live vaccine they used was also effective. Buddle et al. (1984) and Buddle
and Pulford (1984) had also good efficacy by vaccinating lambs, but had no effi-
cacy by vaccinating pregnant ewes. Nettleton et al. (1996) used a commercial
vaccine that was very effective in lambs, as in vaccinated lambs the lesions were
milder than in unvaccinated ones. In literature, there were no studies reported
about the efficacy of the orf vaccine in goats. As it has been shown in our study,
the vaccination of pregnant does 1 month before parturition gives good protection
to neonatal kids, as they had a low morbidity and mortality rate compared with
non-vaccinated controls.
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Michelsen (2002) considered that vaccination failures can be attrib-
uted to the different strain virulence, but Reid HW (2002) assessed that there was
no evidence to suggest that field isolates of different virulence existed. Pye (1990)
had different results in Australia vaccinating sheep with 2 different vaccine strains
(effective, non-effective).
In literature, vaccination failures for the orf virus are not attributed to
the antigenic difference between the vaccine and field strains (Buddle BM, Pulford
HD, 1990; Nettleton PF et al., 1996; Michelsen PGE, 2002). According to Nettleton
PF et al. (1996) a live orf vaccine with an Australian strain had very good efficacy
against the British strains. Our results are also confirmatory, since the French vac-
cine strain of Ecthybel was very effective in protecting the animals of 4 flocks in dif-
ferent areas of northern Greece.
The vaccine was clinically effective in reducing the morbidity and mor-
tality rates in lambs and kids, while the orf lesions were milder in lambs and kids of
vaccinated mothers. The clinical efficacy of the vaccine was further confirmed by
the 2nd year of the study, because the owner of flock 1 refused to vaccinate his
flock, while the owners of the other flocks vaccinated them. There was an in-
creased morbidity and mortality rate in flock 1 compared with the previous year
(when he had vaccinated the animals) and the other 3 flocks, that continued to
have reduced morbidity and mortality due to vaccination. Since the immunity is
not long lasting (McKeever DJ and Reid HD, 1987) and reinfections are frequent,
revaccination appears necessary.
In the present study, antibody levels determination by the ELISA test in
sheep and goats showed an increase after vaccination. The same results have
also been found in other studies with ELISA (Buddle BM, Pulford HD, 1990; Nettle-
ton PF et al., 1996). Yirell et al. (1989) vaccinated SPF Suffolk crossbred lambs
and found an increase in antibody titres post-vaccination using ELISA, although
some animals did not respond. The humoral response is affected by several fac-
tors; one of them is the animal breed (McKeever DJ et al., 1987). In other studies,
an increase on post-vaccination titres was also found with other methods as the vi-
rus neutralization test (VN) and microtitre plate system (Mayr A et al., 1981; Bud-
dle BM et al., 1984; Pye D, 1990). As it has been shown by Housawi FMT et al.
(1992), ELISA is superior to AGID and CFT for orf antibody detection. However, in
orf infections antibody determination is not indicative of the degree of protection
from the disease (Buddle BM and Pulford HD, 1984; McKeever DJ et al., 1987), be-
cause the cellular immune response and related immunomodulatory factors play
a primary part in the protection from orf infection (McKeever DJ et al., 1987; Haig
DM et al., 2002). So, post-vaccination antibody titres for the orf virus could be a
good indicator for previous exposure to the virus, as was the vaccination with a
live vaccine, but not for protection from the disease (Nettleton PF et al., 1996).
From this study, it could be concluded, that vaccination of pregnant
sheep and goats during the last month of gestation with a live orf vaccine (Ecthy-
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bel®-Merial) appears to give good protection to neonatal lambs and kids against
orf virus infection. However, annual re-vaccination seems to be necessary.
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PROCENA ORF VAKCINE NA TERENU KOD STADA OVACA I KOZA SA VISOKOM
NEONATALNOM SMRTNO[]U
N. D. Giadinis, G. Filliusis, S. K. Lafi, N. Panousis, K. Pourliotis, J. Bojkovski,
H. Karatzias
Visok stepen godi{nje smrtnosti neonatalnih `ivotinja doprineo je orf infekci-
jama uo~enim izmedju 2001 i 2004 kod dva stada ovaca i dva me{ovita stada ovaca i koza
u severnoj Gr~koj. Komercijalno dostupna `iva orf vakcina je upotrebljena da bi se za{titila
neonatalna jagnjad i jarad od orf infekcije. Bre|e ovce i koze su vakcinisane subkutano me-
sec dana pre partusa, dok je 10 ovaca i 10 koza u svakom stadu ostalo nevakcinisano i po-
slu`ile su kao negativne kontrole. Vakcina je bila zna~ajno efikasna (P<0,05) u smanjenju
orf lezija i stope smrtnosti kod jagnjadi i jaradi sva ~etiri stada. Tokom slede}e godine, 3 od
4 stada su revakcinisana. Nastavljena je pojava zna~ajno niskog procenta orf lezija i
smrtnosti neonatalnih `ivotinja u revakcinisanim stadima, dok se ponovo pojavio zna~ajan
procenat (P<0,05) orf lezija i smrtnosti neonatalnih `ivotinja kod stada koja nisu revakcioni-
sana. Titri antitela kod vakcinisanih ovaca i koza su bili znacajno poviseni 60 i 105 dana po-
sle vakcinacije, dok su titri kod kontrola ostali niski (P<0,05).
Klju~ne reci: jagnjad, jarad, smrtnost, za{tita, orf, `iva vakcina
OCENKA ORF VAKCINÀ NA MESTE U OTARÀ OVEC I KOZ S VÀSOKOY
NOVORO@DËNNOY SMERTNOSTÃÁ
N. D. Giadinis, G. Filliusis, S. K. Lafi, N. Panousis, K. Pourliotis, J. Boykovski,
H. Karatzias
VìsokaÔ stepenÝ godovoy smertnosti novoro`dënnìh `ivotnìh sodey-
stvoval orf infekciÔm zame~ennìm me`du 2001 i 2004 u dvuh otar ovec i dvuh
sme{annìh otar ovec i koz v severnoy Grecii. Kommer~eski dostupnaÔ `ivaÔ orf
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vakcina upotreblena, ~tobì ohranilisÝ novoro`dënnìe ÔgnÔta i kozlÔta ot orf
infekcii. Beremennìe ovcì i kozì vakcinirovanì podko`no mesÔc tomu nazad do
rodov, poka 10 ovec i 10 koz v ka`doy otare ostalisÝ nevakcinirovanì i vo-
spolÝzovalisÝ kak otricatelÝnìe kontroli. Vakcina bìla zna~itelÝno Ìffek-
tivnaÔ (R<0,05) v umenÝ{enii orf pover`deniy i stavki smertnosti u ÔgnÔt i ko-
zlÔt vseh ~etìrëh otar. V te~enie sleduÓçego goda, 3 i 4 otar revakcinirovanì.
Prodol`eno Ôvlenie zna~itelÝno nizkogo procenta orf pover`deniy i smert-
nosti novoro`dënnìh `ivotnìh v revakcinirovannìh otarah, poka snova poÔvilsÔ
zna~itelÝnìy procent (R<0,05) orf povre`deniy i smertnosti novoro`dënnìh
`ivotnìh u otar, kotorìe ne revakcinirovanì. Titrì antitel u vakcinirovannìh
ovec i koz bìli zna~itelÝno uveli~enì 60 i 105 dney posle vakcinacii, poka ti-
trì u kontroley ostalisÝ nizkie (R<0,05).
KlÓ~evìe slova: ÔgnÔta, kozlÔta, smertnostÝ, ohrana, orf, `ivaÔ vakcina
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